Marker Therapeutics, Inc.

NASDAQ:MRKR

1.25 (USD) • At close April 25, 2025
Bedrijfsnaam Marker Therapeutics, Inc.
Symbool MRKR
Munteenheid USD
Prijs 1.25
Beurswaarde 13,386,250
Dividendpercentage 0%
52-weken bereik 0.95 - 5.99
Industrie Biotechnology
Sector Healthcare
CEO Dr. Juan F. Vera M.D.
Website https://www.markertherapeutics.com

An error occurred while fetching data.

Over Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells

Vergelijkbare Aandelen

Reviva Pharmaceuticals Holdings, Inc. logo

Reviva Pharmaceuticals Holdings, Inc.

RVPH

0.855 USD

Acurx Pharmaceuticals, Inc. logo

Acurx Pharmaceuticals, Inc.

ACXP

0.405 USD

Precipio, Inc. logo

Precipio, Inc.

PRPO

6.03 USD

Healthcare Triangle, Inc. logo

Healthcare Triangle, Inc.

HCTI

0.185 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)